QPI 1007

Drug Profile

QPI 1007

Alternative Names: QPI-1007; siCASP2

Latest Information Update: 02 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quark Pharmaceuticals
  • Developer Biocon; Kunshan RiboQuark Pharmaceutical Technology Co; Quark Pharmaceuticals
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action Gene expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Optic nerve disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Optic nerve disorders
  • Phase II Angle-closure glaucoma

Most Recent Events

  • 29 Jul 2016 Quark Pharmaceuticals has patent protection for QPI 1007 in USA
  • 23 Jun 2016 Phase-II/III clinical trials in Optic nerve disorders in India, Israel, Germany, Australia, Italy, China (Intravitreous)
  • 14 Mar 2016 Quark Pharmaceuticals receives approval from the China Food and Drug Administration and Drug Controller General of India for a phase II/III trial of QPI 1007 for Optic nerve disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top